Methylxanthines: Potential Therapeutic Agents for Glioblastoma

• Autores principales: Daniel Pérez-Pérez (Autor), Iannel Reyes-Vidal (Autor), Elda Georgina Chávez-Cortez (Autor), Julio Sotelo (Autor), Roxana Magaña-Maldonado (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2019-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells...